Efficacy of beta-Lactam/beta-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia
- Gudiol C
- Royo-Cebrecos C
- Abdala E
- Akova M
- Alvarez R
- Maestro-de La Calle G
- Cano A
- Cervera C
- Clemente WT
- Martin-Davila P
- Freifeld A
- Gomez L
- Gottlieb T
- Gurgui M
- Herrera F
- Manzur A
- Maschmeyer G
- Meije Y
- Montejo M
- Peghin M
- Rodriguez-Bano J
- Ruiz-Camps I
- Sukiennik TC
- Tebe C
- Carratala J
Publication date
January 2017
DOIAbstract
beta-Lactam/beta-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum beta-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenem-sparing alternatives for the treatment of BSI due to ESBLs in these patients
Add to ORKG